PHI with neuroencephalomyelopathia optica
How does this condition affect your private health insurance?
Neuroencephalomyelopathia optica, commonly known as Neuromyelitis Optica Spectrum Disorder (NMOSD), is a rare and severe autoimmune inflammatory disorder. It primarily targets the optic nerves (optic neuritis) and spinal cord (transverse myelitis), and sometimes the brain. The immune system mistakenly attacks healthy cells, often aquaporin-4 water channels or myelin oligodendrocyte glycoprotein (MOG). This leads to acute attacks causing vision loss, paralysis, or sensory deficits. The disease typically follows a relapsing course, with each attack potentially causing cumulative and irreversible neurological damage. Prompt diagnosis and ongoing immunosuppressive treatment are vital to manage relapses and preserve neurological function.
PKV Risk Assessment
Individual, specialized PHI providers may still insure you, but with a significant surcharge.
Impact on Your Insurance Policy
Duration of Illness (Initial)
Several days to weeks
Duration of Illness (Lifetime)
Chronic, relapsing disease over a lifetime
Cost of Treatment (Initial)
High, potentially tens of thousands of dollars, due to hospitalization and acute therapies like plasmapheresis or high-dose steroids.
Cost of Treatment (Lifetime)
Very high, potentially hundreds of thousands to millions of dollars, due to ongoing costly immunosuppressive medications and management of relapses and disabilities.
Mortality Rate
Variable; severe attacks can be life-threatening if critical areas are affected (e.g., respiratory centers). Cumulative disability impacts long-term survival.
Risk of Secondary Damages
High. Permanent vision loss, severe motor disability (paralysis), chronic pain, fatigue, bladder/bowel dysfunction, and cognitive impairment are common. Significant psychological impact also occurs.
Probability of Full Recovery
Low. While some recovery is possible after an attack, complete recovery without any residual neurological deficit is rare, especially after severe or repeated attacks.
Underlying Disease Risk
Increased likelihood of co-occurring autoimmune conditions (e.g., Sjogren's syndrome, systemic lupus erythematosus).